Cell and gene therapies require development of fit for purpose analytical tools to support bioprocess development, for biopharmaceutical characterization and lot release testing.
Webinar: Development of sensitive ADA assays using automated acid dissociation in Gyrolab Mixing CD 96
Measuring Anti-Drug-Antibody (ADA) levels is an important part of developing new biologics. The clinical implication of the presence of anti-drug-antibodies in treated patients may include allergic reactions, immune complex toxicity, autoimmune reactions and reduction of efficacy.
Impurity testing of biotherapeutics? Try the new Gyrolab CHO-HCP E3G Kit. Now available in a ready to use kit optimized for Gyrolab® Systems.
Other than specificity, the affinity (KD) of an antibody reagent binding to a drug target is the most important property that drives PK, ADA and NAb assay performance.
Gyros Webinar: Rapid in-solution equilibrium approach to KD determination of biotherapeutic drug candidates
Current technologies for the development of new antibody biotherapeutic drug substances enable the development of very high affinity candidates.